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Abstract
Three further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and
dapagliflozin) have recently been published, adding to the twelve earlier within-class studies. The linagliptin study
(CARMELINA) recruited people with renal disease as well as prior CV events and confirms the overall CV safety
(and other safety) of the dipeptidylpeptidase-4 (DPP4) inhibitors, with no heart failure risk associated with this
agent. However, taken together with the findings from two previous studies of DPP4 inhibitors (sitagliptin and
saxagliptin), the three DPP4 inhibitor CV outcome trials (CVOTs) have highlighted a safety signal regarding risk
of pancreatitis. Like CARMELINA, the albiglutide study (Harmony Outcome) had a very high CV event rate.
Despite being a short duration study, albiglutide showed strong superiority for reduction in the major adverse CV
events (MACE) composite in people with extant cardiovascular disease (CVD), in line with the earlier studies on the
GLP-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide. Positive effects can be detected for all these
medications from before 12 months and continue for the whole study duration. No new safety issues for albiglutide
are identified and the lack of a pancreatitis or a pancreatic cancer signal for this class is now clear. For the sodium–
glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates
strong protection for heart failure in those with CVD, and probably in those with no prior CVD. There is also strong
protection against renal decline with dapagliflozin, with similar risk estimates in DECLARE as previously reported
for empagliflozin and canagliflozin. However, findings for MACE outcomes with dapagliflozin are not concordant
with the empagliflozin and canagliflozin studies, and are not convincingly superior across class and for the longer
term. Care is required when prescribing the SGLT2 inhibitor class of medications to people with foot vascular issues
or prior amputation, and to insulin users in regard of ketoacidosis. In summary, taking into account the findings
from these new studies, it is suggested that a GLP-1RA should be offered to all people with CVD and type 2
diabetes, and SGLT2 inhibitors should be prescribed for those at high risk of heart failure or with progressive
decline in eGFR. DPP4 inhibitors are a safe choice within the glucose-lowering stepped algorithm.
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Introduction and background
Prior to the year 2000, the only glucose-lowering medica-
tion major cardiovascular (CV) outcome trials (CVOTs) in
type 2 diabetes were from the University Group Diabetes
Program and the UK Prospective Diabetes Study
(UKPDS) [1, 2]. Preclinical signals of cardiac adverse
effects with the thiazolidinediones later led the European
regulator to mandate a CVOT for rosiglitazone and pio-
glitazone [3, 4]. However, it was only with the signal for
increased myocardial infarction (MI) in phase 2/3 studies
with rosiglitazone, identified by GlaxoSmithKline in 2006
and Nissen and Wolski in 2007 [5, 6], that concern was
highlighted that neither conventional development
programmes (of >2000 patient-year exposure) nor post-
marketing surveillance (because occurrence of CV events
is unremarkable in the type 2 diabetes population) could
reliably detect increased CV events. Anxieties around oth-
er medications increased that concern [7, 8].
Accordingly, the US Food and Drugs Administration
(FDA) mandated that, after licensing, glucose-lowering
medications should achieve a maximum hazard of 1.30
(upper 95% CI) in a CVOT with a composite endpoint of
first MI, stroke or CV death event [9]. This was applied
even to medications with CVOTs that began before the
mandate was issued [4, 10] and eventually to a new
insulin analogue [11]. Prior to the studies highlighted in
this review, that is those with results presented and pub-
lished in October/November 2018, none of the twelve
CVOTs would have failed the ‘1.30 test’, although some
studies did have a CV-related adverse signal and, in
others, safety signals were detected for non-CV outcomes
[3, 4, 12–16].
The three most recently reported CVOTs were on
a l b i g l u t i d e (Ha rmony Ou t c ome ) , l i n a g l i p t i n
(CARMELINA), and dapagliflozin (DECLARE-TIMI
58) [17–19], and hence allow discussion of the findings
of three classes of glucose-lowering agents. It is noted
that other studies will be reported on in 2019 (with top
level announcements already made), namely REWIND
(dulaglutide CVOT), PIONEER 6 (oral semaglutide,
phase 3 CVOT), CREDENCE (canagliflozin renal out-
come study) and, later, CAROLINA (linagliptin vs
glimepiride study) [20–23]. The questions that might be
asked a priori of a CVOT in a field where previous
medications in the same class have already been reported
on are: (1) are the findings in a comparable population;
(2) are the findings consistent with previous results; (3)
do the findings assist in understanding unexpected results
from previous studies; (4) are there any novel insights or
signals worth consideration; and (5) how should this fur-
ther study affect clinical guidelines in relation to this
class of drug?
Methods
A systematic search was not performed for this review, as
findings for the criteria that would have been used to reject
an upper 95% CI of hazard of <1.30 (a priori study power for
major adverse CV events [MACE; CV death, MI, stroke], or
prima facie post-priori power to detect superiority in a single
study) are limited to a handful of recently published studies.
Moreover, meta-analyses were not carried out either because
the study findings are so consistent and robust that it would
not have been useful (e.g. MACE for the studies on
dipeptidylpeptidase-4 [DPP4] inhibitors) or because the stud-
ies are so disparate in the population and design that the meta-
analysis findings would not apply to any group of people with
diabetes in clinical practice (e.g. studies on the sodium–
glucose cotransporter-2 [SGLT2] inhibitors).
Findings are given as HRs, concentrating on 95% CIs rath-
er than central estimates, unless otherwise stated. p values are
not used, except with caution to identify possible sub-group
interactions or where strong enough (p < 0.001) to justify pos-
itive consideration of a secondary or observational outcome
(for example, heart failure and CV death in the EMPA-REG
OUTCOME study [13]).
CARMELINA: a CVOT of linagliptin
Design and populations CARMELINA [18] complements
two previous placebo-blinded, standard-of-care-controlled,
CVOTs of DPP4 inhibitors (ignoring the EXAMINE study
of alogliptin in people with recent acute coronary syndrome
[ACS] [24]); like the TECOS study on sitagliptin and SAVOR-
TIMI 53 (saxagliptin) (hereafter referred to as SAVOR),
CARMELINA was performed in people with type 2 diabetes
and extant CV disease, or at high risk of CVevents. However,
there are some differences in the populations used between
these studies [10, 12, 18] (Table 1). CARMELINA recruited
people with previous CVevents and micro/macroalbuminuria,
or those with some impairment of eGFR (<75 ml min−1
[1.73 m]−2) with macroalbuminuria, or with more severe renal
impairment (eGFR <45 ml min−1 [1.73 m]−2) alone. As a re-
sult, 62% of the population had eGFR <60 ml min−1
[1.73 m]−2. Of note, linagliptin is not known to have any spe-
cial effect on the kidney. This also resulted in two overlapping
but distinct populations: one with extant CV disease (CVD;
57%) and one with renal disease (eGFR <60 ml min−1
[1.73 m]−2 or macroalbuminuria (74%); 33% of the population
were in both groups [18]. This limits generalisability of the
findings as, while the highest event rates were seen in those
with more advanced renal impairment rather than prior CV
disease, it is unclear how results from the combined population
might be applied to a general diabetes population. However,
the interaction of renal groups and major study outcomes are
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presented in the supplementary materials of the original publi-
cation and, while the numbers within subgroups provide low
power, no concerns are obvious [18].
While the three studies of DPP4 inhibitors agree that short-
term (<3 year) outcomes do not differ between DPP4 inhibi-
tors and standard of care, they are less similar regarding the
studied populations than the previous paragraph might imply.
CARMELINA, like SAVOR, had only a small Asian popula-
tion (and all three studies include barely any black/Afro-
Caribbean people) but TECOS recruited in Asia (Table 1).
More strikingly, CARMELINA had very high baseline use
of insulin and high rates of new insulin starters during the
study (Table 1), to the extent that it could be argued that the
results are only generalisable to insulin-treated populations.
The generalisability issue is further marred by the very high
event rate in this study (Table 1). Event rates in CVOTs have
shown inflation over the years, but the rate of 5.6% per year
reported in the placebo group has only previously been
exceeded in post-ACS studies. The chronic kidney disease
(CKD) population does have high CVD rates, which may have
contributed to the high event rate observed in this study. That the
observed event rate is far in excess of previous studies recruiting
CANVAS Program (CANagliflozin cardioVascular Assessment Study [CANVAS] plus CANVAS-Renal [CANVAS-R])
CV outcome studies of canagliflozin 
CARMELINA (CArdiovascular and Renal Microvascular outcomE study with LINAgliptin)
CV outcome study of linagliptin 
CAROLINA (CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes)
CV outcome study of linagliptin vs glimepride 
CREDENCE (Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation)
Kidney outcome study of canagliflozin
DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events-TIMI 58)
CV outcome study of dapagliflozin
ELIXA (Evaluation of LIXisenatide in Acute Coronary Syndrome)
CV outcome study of lixisenatide
EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients)
CV outcome study of empagliflozin
EXAMINE (EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE)
CV outcome study of alogliptin 
EXSCEL (EXenatide Study of Cardiovascular Event Lowering)
CV outcome study of exenatide modified release (long-acting)
Harmony Outcome
CV outcome study of albiglutide
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results)
CV outcome study of liraglutide 
PIONEER-6 
CV outcome study (phase 3) of oral semaglutide
REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes)
CV outcome study of dulaglutide 
SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-TIMI 53)
CV outcome study with saxagliptin
SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type
2 Diabetes)
CV outcome study of s.c. semaglutide
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
CV outcome study with sitagliptin
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only a secondary prevention population (e.g. PROactive,
TECOS), or the intensive therapy studies ACCORD and
ADVANCE [3, 10, 25, 26], leads to unanswered questions as
to how the population was recruited in CARMELINA. Were
these perhaps cardiology patients with diabetes rather than peo-
ple with diabetes with CV/renal disease?
Findings The above being said, the headline findings are entirely
consistent with TECOS and SAVORand confirm,with adequate
power, that in the short-term linagliptin shows no CV safety
signal (Table 2). The heart failure signal unexpectedly observed
with saxagliptin [12] was not found in CARMELINA and, with
its absence also in TECOS [10], it is now clear that this is not a
class effect. The EXAMINE (alogliptin) data are non-
contributory to this evaluation as its CIs for heart failure are very
wide thus being consistent with any of the other three studies
[27]. Useful sensitivity analyses were performed, including per-
protocol, a more robust test of non-inferiority. Breakdown of
MACE by its components suggests there is no reason to doubt
the validity of this composite endpoint (unlike with SGLT2 in-
hibitors, as discussed further below), but CARMELINA does
not have the power to be as convincing as TECOS in regard to
this (Table 2). The positive interaction test result for MACE
based on HbA1c levels is unadjusted and one of 25 such tests
[18], and thus unlikely to be a reliable finding.
A major secondary endpoint in CARMELINA was the
composite endpoint for kidney disease, prospectively allocat-
ed the greater part of the alpha power at that level. This was
mainly defined as a confirmed >40% decline in eGFR, with
minor contributions (due to low event number) from end stage
renal disease and renal death. As might be anticipated given
the SAVOR and TECOS results, this did not differ between
linagliptin vs standard of care (HR 1.04 [95% CI 0.89, 1.22])
[18, 28, 29]. TECOS showed a sustained decline in eGFR
with sitagliptin use, to a clinically insignificant extent [28],
but CARMELINA does not report this data.
The authors of CARMELINA also present findings of two
other composites (nephropathy and microvascular disease),
both of which were driven by progression of albuminuria
and showed advantage to linagliptin vs standard-of-care.
Albuminuria in type 2 diabetes is, however, a marker of vas-
cular inflammation rather than microvascular disease and pos-
itive findings have been reported for a wide range of glucose-
lowering medications, including sulfonylureas, PPAR-γ
Table 1 Comparative character-
istics of DPP4 inhibitor CVOTsa Variable SAVOR [12] TECOS [10] CARMELINA [18]
Drug Saxagliptin Sitagliptin Linagliptin
Population (n) 16,492 14,671 6979
Follow-up (years) 2.1 3.0 2.2
Known atherosclerotic CVD 79 100 57
Renal impairmentb 16 23 62
Female sex 33 29 37
Insulin therapy
Baseline 41 23 57
Any time 45 32 73
HbA1c (mmol/mol) 64 ± 15 55 ± 6 64 ± 11
HbA1c (%) 8.0 ± 1.4 7.2 ± 0.5 8.0 ± 1.0
Ethnicity
Asian 11 22 9
Black 3 3 6
Hispanic 16 12 36
Failed to finish on medication 19 23 26
CVeventsc (n)
First MACE 1222 1211 854
First MACE+ NG 1390 922
Placebo event rate (%/year) 3.6 4.2 5.6
Data are % unless otherwise stated
Some variables have been calculated by the author of this review and may be inaccurate to one significant figure
a Excluding EXAMINE, which was conducted in individuals with prior ACS
bGiven as: <60 ml min−1 [1.73 m]−2 in TECOS and CARMELINA; <51 ml min−1 [1.73 m]−2 in SAVOR
cMACE: CV death, MI, stroke; MACE+: CV death, MI, stroke, acute coronary event
NG, not given
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agonists, other DPP4 inhibitors and GLP-1 receptor agonists
(GLP-1RAs) [2, 14, 26, 28–30]. This is therefore not a re-
markable or useful finding.
Safety and tolerabilityDPP4 inhibitors have an excellent safe-
ty and tolerability record, the exceptions being the heart failure
signal in SAVOR (as discussed above) and the possibility of
increased risk of pancreatitis. With the relatively small study
population exposed to linagliptin (n = 3494) for only 1.9 years
on average, CARMELINA does not answer any question re-
garding low-frequency safety signals, including pancreatitis.
Indeed, the data on confirmed acute pancreatitis from the three
DPP4 inhibitor studies discussed here are not strong, even
after combined analysis (events: n = 49 on DPP4 inhibitor vs
n = 26 on placebo). Hence, although the signal is a clear, it is
by nomeans a certain one and provides no reassurance that the
drugs are safe in this respect (Table 3).
Summary and consequences The CARMELINA findings are
not derived from a population that is directly comparable with
TECOS and SAVOR but are consistent with findings from
these studies. The absence of a heart failure signal makes it
more likely that the ‘finding’ in SAVOR is due to chance.
Nonetheless, given that sitagliptin and linagliptin do not show
this heart failure signal, these agents would appear to be the
better choice over saxagliptin and any other DPP4 inhibitor
without a proper CV study in a regular diabetes populations,
unless the individual’s risk of heart failure is known to be low.
However, the absence of any clear benefit, except for their
excellent tolerability, would seem to put this class behind
medications showing some CV or kidney disease advantage,
where this need is identified (see below for GLP-1RAs and
SGTL2 inhibitors).
Harmony Outcome: a CVOT of albiglutide
Design and populations Albiglutide is no longer actively
marketed, but the mixed findings from other GLP-1RA
CVOTs mean that the findings from Harmony Outcome [17]
(hereafter referred to as Harmony) are interesting and useful.
As with CARMELINA, however, the study population was rel-
atively small, particularly for such a short study duration
(Table 4). The very high event rate in the placebo group (5.9%
per year) was unexpected [31] and again raises questions of
generalisability to ambulant diabetes populations, even to those
with extant CVD, as was required for entry into this study.
Harmony complements three other placebo-blinded,
standard-of-care-controlled CVOTs of GLP-1RAs, excluding
the ELIXA study of lixisenatide in people who had recent
ACS [14, 15, 32, 33]. The three prior studies included indi-
viduals with CV risk factors but no prior CVD, and, unlike
Harmony, two of these studies had total event numbers that
were clearly aimed at testing superiority [14, 33].
Nevertheless, hierarchical testing for superiority after inferior-
ity analysis was pre-specified in Harmony. SUSTAIN-6 was a
phase 3 study designed to exclude the 1.80 (not 1.30) upper
confidence limit for hazard (this is perceived by some as a
limitation of the study) [15, 34]. As with CARMELINA,
SUSTAIN-6 and LEADER, Harmony had very high rates of
combination insulin therapy, with 62% of participants taking
insulin by the study end (Table 4); this too raises concern over
generalisability of the findings. Indeed, the test for interaction
for baseline use or non-use of insulin nearly reaches conven-
tional statistical significance (p = 0.053) but with CVoutcome
advantage to the non-insulin group, these findings thus miti-
gating possible concern.
Harmony had a very low proportion of Asian and black
participants (Table 4), indeed to an extent that any determina-
tion of interaction of the primary outcome between ethnic
groups is unsound. None of the GLP-1RA studies are then
directly applicable to the majority of the world’s population
with type 2 diabetes. In Harmony, there was no interaction for
the primary outcome between subgroups of Hispanic and non-
Hispanic white ethnicity.
Findings Despite being powered for non-inferiority, in
Harmony the central HR for MACE was 0.78, which, with
Table 3 Acute pancreatitis and
pancreatic cancer findings for the
incretin CVOTs
Study Drug Acute pancreatitis Pancreatic cancer Adjudication Reference
SAVOR Saxagliptin 17 vs 9 5 vs 12 Pancreatitis [12]
TECOS Sitagliptin 23 vs 12 9 vs 14 Both [10]
CARMELINA Linagliptin 9 vs 5 11 vs 4 Both [18]
LEADER Liraglutide 18 vs 23 13 vs 5 Both [14]
SUSTAIN-6 Semaglutide (s.c.) 9 vs 12 1 vs 4 Both [15]
EXSCEL Exenatide (MR) 26 vs 22 15 vs 16 ‘Confirmed’ [33]
Harmony Albiglutide 10 vs 7 6 vs 5 Pancreatitis [17]
Data are presented as number of participants who reported in the study as having developed pancreatitis/pancre-
atic cancer; for active medication vs standard-of-care (placebo)
MR, modified release (long-acting)
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766 primary events (Table 4), brings the upper CI down to
0.90 (Table 2), which is a more comfortable margin over
equivalence to standard of care than for the three earlier
GLP-1RA studies (Tables 2 and 5). While numerically this
is driven by MI events, the HRs of the components of
MACE in this study are consistent with the primary outcome
and each other (Table 2). At the doses used in Harmony,
albiglutide was less efficacious in lowering glucose and body
weight than the other agents in the other CV-positive studies,
consistent with phase 3 findings [35], but the CV outcomes
with albiglutide are at least as impressive. These findings sug-
gest that the beneficial effect of albiglutide on CVoutcomes is
not mediated by changes in plasma glucose or energy balance,
and that the dose–response curve for vascular protection is not
coincident with that for glucose-lowering between the four
GLP-1RA agents investigated in LEADER, SUSTAIN-6,
EXSCEL and Harmony. These findings perhaps even suggest
that the effect of this class of drug on CV risk may not be
mediated through the classic GLP-1 receptor or, alternatively
that they may reflect differential tissue access [36].
It is possible to put together a panel of HRs and their CIs for
the four GLP-1RA CVOTs for MACE, its components and
all-cause mortality (Table 5). If this is done, the best of these
five variables (using the criteria of best upper CI) are scattered
amongst the studies, with EXSCEL and LEADER tying for
all-cause death. This suggests that the findings are drawn by
chance from the same population of effect. Harmony, then,
can be regarded as entirely consistent in terms of CVoutcomes
with the other three agents.
Tests for subgroup interaction in Harmony, with a couple of
p values <0.05, are as to be expected for multiple testing. The
‘significant’ findings for age and smoking [17] are both in-
consistent in direction within the subgroups.
Harmony is unusual in that the phase 2/3 programme for
albiglutide included, by design, a number of studies that contin-
ued for at least 2 years, in which MACE events were prospec-
tively adjudicated [37]. Indeed, composite exposure to
albiglutide and placebo at phase 2/3 was not very different from
that in Harmony Outcome [37]. However, the number of people
withMACE events was just 105 (HR 0.99 [95%CI 0.65, 1.49]),
emphasising (as has been shown with rosiglitazone and DPP4
inhibitors) how phase 2/3 studies with low numbers can give
misleading findings for CVoutcomes [6, 38].
Safety and tolerability Interestingly, the rather patient-
unfriendly injection system for weekly albiglutide in
Table 4 Comparative character-
istics of GLP-1RA CVOTsa Variable LEADER [14] SUSTAIN-6 [15] EXSCEL [33] Harmony [17]
Drug Liraglutide Semaglutide Exenatide (MR) Albiglutide
Population (n) 9340 3297 14,752 9463
Follow-up (years) 3.8 2.1 3.2 1.6
Known atherosclerotic CVD 81 71 73 100
Renal impairmentb 23 24 22 23
Female sex 36 39 38 31
HbA1c (mmol/mol) 72 ± 16 72 ± 16 64 72 ± 16
HbA1c (%) 8.7 ± 1.5 8.7 ± 1.5 8.0 8.7 ± 1.5
Insulin therapy
Baseline 45 58 14 59
Any time 81 75 26 62c
Ethnicity
Asian 10 8 10 5
Black 8 7 6 2
Hispanic 12 15 21 21
Failed to finish on medication NG 20 44 26
CVevents, first MACE (n)d 1302 254 1744 766
Placebo event rate (%/year) 3.9 4.2 4.0 5.9
Data are % unless otherwise stated
Some variables have been calculated by the author of this review and may be inaccurate to one significant figure
a Excluding ELIXA, which was conducted in individuals with prior ACS
bDefined as <60 ml min−1 [1.73 m]−2
c Per cent on insulin at latest observation
dMACE: CV death, MI, stroke
MR, modified release (long-acting); NG, not given
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Harmony did seem to lead to a higher discontinuation rate
from study medication than for semaglutide (allowing for ex-
posure period) (Table 4). This problem was also noticeable for
the original exenatide modified release formulation (MR;
long-acting) in the EXSCEL study over a longer exposure
period [33]. Albiglutide was already known to show a modest
degree of gastrointestinal intolerance and a low but measur-
able rate of injection-site reactions [39]; these findings were
confirmed in Harmony [17]. The data for other pre-defined
adverse outcomes of special interest, including pancreatitis
(Table 3), are not concerning. However, actual exposure to
albiglutide in Harmony was low (~7000 person-years), so
the power to detect uncommon side effects was low.
Harmony also has little power to address the issue of ac-
celerated progression of retinopathy with GLP-1RA use,
which was raised by SUSTAIN-6, with a weak signal being
revealed in LEADER [14, 15]. However, the absence of this
issue with albiglutide would be consistent with the glucose-
lowering hypothesis, semaglutide being much more effective
in this regard [15].
Summary and consequences Because albiglutide is no longer
promoted for use, the findings here are of indirect significance
and importance. Nevertheless, the observed clear benefits re-
garding CV outcomes confirms that there is a class effect of
clinical significance, probably extending to all longer-acting
agents (Tables 2 and 5). The divergence between CVand glu-
cose-/body weight-lowering efficacy is important for our un-
derstanding of how the GLP-1RA class mechanistically
achieves amelioration of MACE events within 12 months of
taking the medication, with this effect (according to Kaplan–
Meier curves) continuing to the end of each study. While injec-
tion therapies are not always welcome, it does now seem that
the offer of CV protection cannot be denied to anyonewith type
2 diabetes and extant CVD, if resources allow. No serious
safety signals have emerged for this class.
The detailed results of the REWIND study are awaited
(expected June 2019) and should throw further light on the
issue of whether people without extant CVD can benefit from
prescription of GLP-1RAs [20]. Details of the CVD/non-
CVD subgroups within REWIND and the interactions be-
tween them will be needed to assess the implications for the
non-CVD population.
DECLARE-TIMI 58: a CVOT of dapagliflozin
Design and populations DECLARE-TIMI 58 [19] (herein re-
ferred to as DECLARE) joins the EMPA-REG OUTCOME
study and the CANVAS Program (composed of two studies)
as reported CVOTs of SGLT2 inhibitors [13, 16, 19].
However, these three studies are of different designs;
DECLARE, like the original CANVAS study, had a majority
population (59%) without extant CVD (Table 6). However,
because of its very large base population and relatively long
duration of follow-up, the power of this new study for those
with CVD remained relatively good. This mixed population
might have allowed a better assessment of effects in those with
and without CVD, which was not possible in EMPA-REG
OUTCOME (in which 99% of participants had known athero-
sclerotic CVD) and was only possible with limited power in
the CANVAS Program. However, with the exception of heart
failure and the renal composite outcome, DECLARE’s head-
line findings are less certain than expected (Table 2).
DECLARE had a somewhat lower proportion of partici-
pants on insulin therapy at baseline (mitigated for safety by the
high exposure) and a better sex mix than in the EMPA-REG
OUTCOME (empagliflozin) study (Table 6). However, the
Table 5 GLP-1RA CVOTs with
the best confidence for superiority
and worst confidence for inferi-
ority (excluding ELIXA) by
MACE, MACE components and
all-cause death
Best upper CIa Worst upper CIb
Variable Study HR (95% CI) Study HR (95% CI)
MACEc Harmony 0.78 (0.68, 0.90) EXSCEL 0.91 (0.83, 1.00)
MId Harmony 0.75 (0.61, 0.90) EXSCEL 0.97 (0.85, 1.10)
Stroked SUSTAIN-6 0.61 (0.38, 0.99) Harmony 0.86 (0.66, 1.14)
CV death LEADER 0.78 (0.66, 0.93) SUSTAIN-6 0.98 (0.65, 1.48)
All death LEADER
EXSCEL
0.85 (0.74, 0.97)
0.86 (0.77, 0.97)
SUSTAIN-6 1.05 (0.74, 1.50)
The chosen criteria will be affected by study power and play of chance, as well as underlying medication efficacy
a Lowest upper 95% CI
bHighest upper 95% CI
cMACE: CV death, MI, stroke
d Fatal and non-fatal
Source: Harmony [17]; SUSTAIN-6 [15]; LEADER [14]; EXSCEL [33]
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number of participants who were of black ethnicity is again
too small to make meaningful conclusions regarding differ-
ences between ethnic groups. Further, due to the exclusion of
people with eGFR <60 ml min−1 [1.73 m]−2, meaningful data
in this group is not provided, with one useful exception
(discussed below).
This large study had a longer follow-up (4.2 years) com-
pared with the other SGLT2 inhibitor CVOTs, and a low dis-
continuation rate when taking the study duration into account;
hence, in DECLARE, exposure to dapagliflozin was usefully
high (Table 6).
Findings Discussion of the findings of DECLARE is complicat-
ed due to the multiple composite endpoints analysed, each of
these often driven by one component and, therefore, invalid. A
composite endpoint analysis is only valid if the components of
the composite behave similarly or, if they do not, if they are of
similar clinical impact. For example, CV death plus
hospitalisation for heart failure is a composite that makes sense
in heart failure studies but not in diabetes-care studies. Here, the
hazard findings are of a 5–27% reduction for the composite but,
when each component is analysed individually, this is clearly
driven by a strong reduction in heart failure (HR 0.73 [95%
0.61, 0.88]), with no evidence of change in CV death (HR 0.98
[0.82, 1.17]; Table 2). The effect of dapagliflozin on heart failure
risk is consistent with that for empagliflozin and canagliflozin
[13, 16]. Further, for the composite, this is a clear finding on
interaction testing in both the CVD and non-CVD subgroups.
Although information on these subgroups is unavailable for
canagliflozin, this has been hypothesised from a large observa-
tional study of SGLT2 inhibitors [40].
The MACE findings in DECLARE are presented as being
of interest for non-inferiority testing only, but clearly do not
support superiority (Table 2). They are, however, otherwise
useful since the data from EMPA-REG OUTCOME and
CANVAS are not easy to interpret. For example, the form of
the Kaplan–Meier curves is different between the three stud-
ies: in EMPA-REGOUTCOME and CANVAS Program, after
18 and 24 months, respectively, the lines converge or are par-
allel (meaning no further advantage from the drug); in
DECLARE, however, the lines begin to diverge in a way that
is indicative of putative advantage with dapagliflozin use [13,
16, 19]. Overall, there is no evidence of anyMACE advantage
in the non-CVD group on subgroup analysis [19]. The con-
servative interpretation of these findings would be that the
differences between studies (medications) are due to chance
and that there is no reliable evidence of MACE advantage
with use of SGLT2 inhibitors, except perhaps in the short-
Table 6 Comparative character-
istics of SGLT2 inhibitor CVOTs Variable EMPA-REG OUTCOME
[13]
CANVAS Programa
[16]
DECLARE
[19]
Drug Empagliflozin Canagliflozin Dapagliflozin
Population (n) 7020 10,142 17,160
Follow-up (years) 3.1 3.6b 4.2
Known atherosclerotic CVD 99 66 41
Renal impairmentb 26 20 7
Female sex 29 36 37
HbA1c (%) 8.1 ± 0.8 8.2 ± 0.9 8.3 ± 1.2
HbA1c (mmol/mol) 65 ± 9 66 ± 10 67 ± 13
Insulin therapy
Baseline 48 50 41
Any time 8 NG NG
Ethnicity
Asian 22 13 13
Black 5 3 3
Hispanic 18 NG 15
Failed to finish on medication 25 30 23
CVevents, first MACE (n)c 772 1011 1559
Placebo event rate (%/year) 4.4 3.2 2.4
Data are % unless otherwise stated
Some variables have been calculated by the author of this review and may be inaccurate to one significant figure
a Composite median of two studies combined; individual study follow-up, 5.7 and 2.1 years
b Defined as <60 ml min−1 [1.73 m]−2
cMACE: CV death, MI, stroke
NG, not given
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term. This interpretation even then would apply only to
high-risk individuals with extant CVD, as observed in
CANVAS [41].
Furthermore, the MACE components also behave different-
ly between the SGLT2 inhibitor studies (Table 2). In EMPA-
REG OUTCOME the HRs were very different (to the extent
where empagliflozin has now been granted a US licence for the
prevention of CV death only), while, in CANVAS, the HRs for
the individual components were fairly consistent (thus,
canagliflozin now has a US licence for CVD prevention) [42,
43]. In DECLARE, the findings for theMACE components are
mostly consistent, albeit with no suggestion of superiority, and
with, as noted above, no effect on risk of CV death.
An issue here is stroke; the SGLT2 inhibitors reduce blood
pressure to a seemingly useful degree, consistent with their
volumetric effects, but stroke hazard was not reduced in any
of the SGLT2 inhibitor CVOTs and, indeed, there was a signal
for harm with empagliflozin (Table 2). An explanation may be
that the increases in haemoglobin/haematocrit induced by this
class of agents, and the blood volumetric/hypotensive effect,
are countering the blood pressure advantage, preventing
stroke reduction. This may have clinical consequences for
those with diabetes who experience a transient ischaemic at-
tack (TIA) or stroke while taking these medications, and
others at particular risk of such an event.
DECLARE gives evidence for the impact of dapagliflozin
on two renal composites, one including CV death and renal
death and the other (more conventionally) only renal death,
with both composites also including end stage kidney failure
and a 40% reduction in eGFR. The latter composite provided a
very strong finding (HR 0.53 [95% CI 0.43, 0.66]), consistent
with EMPA-REG OUTCOME and CANVAS. This finding is
driven by the eGFR component (judging by the steps in the
Kaplan–Meier curve), although we do not yet have crucial
information on rate of eGFR decline in DECLARE partici-
pants and whether this finding is preserved below an eGFR of
60 ml min−1 [1.73 m]−2 [44, 45]. However, despite the few
participants in DECLARE with an eGFR <60 ml min−1
[1.73 m]−2 (thus only 59 events for this renal composite), the
interaction analysis across the spectrum of eGFR in the pop-
ulation is consistent by subgroups.
Safety and tolerability The DECLARE findings are, in gener-
al, neutral for safety and tolerability except for genital infec-
tions, which may account for the majority of the excess in
discontinuations [19]. Notably, there is a curious absence of
an excess of reports vs placebo related to volumetric effects.
Toe amputations and subsequent higher-level amputations
were raised as an issue with SGLT2 inhibitor use by the
CANVAS study and by observational studies [16, 46]. These
were not increased in DECLARE, but it is not made clear
whether a signal may have been developing before preventa-
tive measures were put into place (in response to the
CANVAS findings). In DECLARE, peripheral vascular disor-
der as an adverse event doubled with dapagliflozin use, but
numbers of events are small. Ankle fractures were numerically
higher on dapagliflozin vs placebo, and humerus fractures
were lower. Diabetic ketoacidosis numbers in the main text
(which are substantially different to those reported in the sup-
plementary tables in the publication) were approximately dou-
bled in the dapagliflozin group; this was said to be mainly an
effect in the insulin-treated population [19]. The 0.17% excess
rate of ketoacidosis with dapagliflozin vs placebo over the
study duration would, if all ketoacidosis events were in the
insulin-treated group, imply an excess rate of approximately 1
per 1000 people per year. The severity of these ketoacidosis
events is unclear.
Summary and consequences The disparity of the design of
and findings from the CVOTs for empagliflozin, canagliflozin
and, now, dapagliflozin, means that some uncertainty still re-
mains, with the current study not adding much clarity.
However, the exceptions are very important clinically, with
renal protection being perhaps the most significant of these.
Even in the absence of longitudinal eGFR data from
DECLARE, the findings regarding renal protection are strong
and consistent between the three studies; hence, this is clearly
a class effect. The results of the CREDENCE study (of
canagliflozin) are not yet available in detail, but the primary
endpoint is renal outcome and the study closed early because
of a strong finding of efficacy on interim analysis [21]. This
kidney protection by SGLT2 inhibitors is possibly the biggest
clinical gain in diabetes care since laser photocoagulation and
statins. Furthermore, heart failure protection was consistently
observed in the SGLT2 inhibitor CVOTs and, thus, this is also
a clear class effect. In both these areas DECLARE is important
because it has provided an opportunity to perform subgroup
analyses, which indicate that, compared with standard of care,
the relative effects of dapagliflozin are as strong for the non-
CVD population as they are for the CVD population.
Other than the beneficial impact on renal events and heart
failure, the advantages, and indeed side effects, of these med-
ications are unclear, both individually and as a class. Unlike
EMPA-REG OUTCOME, the benefits regarding CV death
with SGLT2 inhibitors was not found in CANVAS or
DECLARE. This is perhaps owing to the beneficial impact
of empagliflozin on heart failure in a particularly high-risk CV
population, with the placebo group in EMPA-REG
OUTCOME having a three times higher CV death rate than
in DECLARE [19, 47]. For EMPA-REG OUTCOME, the
very divergent findings for CV death and stroke invalidate,
for clinical and statistical purposes, the MACE finding [13],
while the findings for MACE in DECLARE are equivocal
[19]. For the CANVAS Program, MACE is improved only
for the majority subgroup with prior CVD, with no clear ev-
idence of advantage after 24 months [16, 41]. Though
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underpowered as an individual MACE component in all three
studies, only the MI effect seems consistent between the
CVOTs for SGLT2 inhibitors, with no heterogeneity observed
following meta-analysis of these studies [47].
The findings of increased fracture rate with canagliflozin in
CANVAS, though consistent with time, were clearly absent in
CANVAS-R and do not appear with the other SGLT2 inhibitor
agents. The findings fromCREDENCEmay help to shed light
on this matter.
In terms of risk of amputation, a problem is that the data
collected in the EMPA-REG OUTCOME study was apparently
not sufficient to address the question with confidence [48]. In
addition, in DECLARE, once aware of this issue, the problem
is likely to have been ameliorated by avoiding SGLT2 inhibitor
use if there had been a prior amputation, and stopping the med-
ication if risk of peripheral ischaemia or infection appeared.
Neither EMPA-REG OUTCOME nor CANVAS appear able
to address the potential ketoacidosis issue with SGLT2 inhibitor
use. However, on the basis of data from DECLARE [19], it is
both a real and a low-frequency problem in people using insulin
alongside dapagliflozin, although for reasons still unclear.
Overall conclusion and messages
for guidelines
Clearly the three recent CVOTs provide knowledge to help
develop diabetes guidelines and clinical management algo-
rithms and protocols. Within the DPP4 inhibitor class, the
linagliptin findings (from CARMELINA) perhaps have the
least impact, with no reach beyond glucose-lowering, except
perhaps in confirming the absence of a class adverse effect on
heart failure and confirming safety in the presence of renal
impairment. A lingering doubt remains over increased risk
of pancreatitis with DPP4 inhibitor use. Nevertheless, the
DPP4 inhibitors remain the best tolerated of any glucose-
lowering medications and, therefore, they should retain their
position in the stepped approached to diabetes therapy, when
other agents are not specifically indicated or preferred [49].
The study findings for the GLP-1RAs (including the new
Harmony findings) indicate that this class of drugs does not have
a pancreatitis signal. This suggests that the possible increase in this
signal with the DPP4 inhibitors does not occur through increased
GLP-1 concentrations, but rather they may be affecting degrada-
tion of some other mediator relevant to the pancreatic vasculature
or ducts, but this is speculative. GLP-1RAs have a relatively early
beneficial effect on already damaged arteries, which persists over
time,with evidence for both protection forMI and stroke. That this
effect is seen with albiglutide, which has relatively low potency
(clinically), might hint that it is not mediated through the classical
GLP-1 receptor pathway. However, these findings could also be
caused by the albumin moiety of this medication, which may
prevent access to GLP-1 receptors in some sites, while the
endothelium and inflamed arterial wall allow direct access [36].
Acylated GLP-1RAs, like liraglutide and semaglutide, could also
have better access to hypothalamic centres. It has also been spec-
ulated that the human sequence medications have intrinsic advan-
tage for CV protection over the exendin peptides, but this does not
fit with our knowledge of receptor interactions [36]. Nonetheless,
GLP-1RAs are now clearly indicated in people with diabetes and
extant CVD, whether a weight-loss effect is desired or not [49].
The remaining negatives of GLP-1RAs are administration via
injections and gastrointestinal side effects. In summary, the find-
ings from the Harmony study do not seem to change the recent
suggestions of the EASD/American Diabetes Association (ADA)
Consensus Group [49].
The clinical positioning of the SGLT2 inhibitors is less
easy. Clearly, if there is a risk of heart failure, these medica-
tions are indicated and perhaps we should now be performing
pro brain natriuretic peptide (proBNP) estimations as part of
annual surveillance of individuals with diabetes. However, it
is not clear whether SGLT2 inhibitors should be used merely
because of extant CVD. It is clear that if eGFR is declining,
particularly if it is declining through 60 ml min−1 [1.73 m]−2
but above 30 ml min−1 [1.73 m]−2, then these agents are
strongly indicated. Precautions, including continuing foot sur-
veillance, are mandatory in anyone with prior peripheral vas-
cular problems, or those developing these problems, while on
SGLT2 inhibitor-based medications. Use in people on insulin
therapy should only be undertaken when users are aware of
the small risk of ketoacidosis, and with the appropriate con-
tinuing education to counter this risk.
To conclude, what does this mean for CVOTs in general?
From the point of view of MACE safety, they have been a
complete failure, with no issues identified. Unlike the PPAR-γ
agonists, for which a preclinical signal had been shown to
exist, no CV issues have arisen with use of DPP4 inhibitors,
GLP-1RAs and SGLT2 inhibitors, apart from the heart failure
signal with saxagliptin. Of course, the benefits of these drugs
(discussed above) have been evidenced by the trials discussed
in this review, but not as mandated by the US FDA. One view
is that large pragmatic safety studies ought to continue, not
specifically directed at CVD, but including brain health, ma-
lignancy, bone health and the like, with directed superiority
studies as felt appropriate by manufacturers and the academic
community. An exception would be where a preclinical or
phase 2/3 safety signal had been found.
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